Research graph
References from Oral mucositis risk with EGFR tyrosine kinase inhibitor monotherapies and combination regimens in non-small cell lung cancer: a systematic review and network meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics, 2025
10.3322/caac.21871 · 2025 · External reference
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
10.1016/j.ctrv.2024.102824 · 2024 · External reference
Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: A meta-analysis
10.1007/s40291-021-00563-1 · 2022 · External reference
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
10.18632/oncotarget.12587 · 2016 · External reference
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches
10.1038/s41571-025-01085-z · 2026 · External reference
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
10.1093/annonc/mdx704 · 2018 · External reference
Overview of current systemic management of EGFR-mutant NSCLC
10.1093/annonc/mdx702 · 2018 · External reference
Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology
10.1007/s40264-018-0772-x · 2019 · External reference
Mucosal injury from targeted anti-cancer therapy
10.1007/s00520-006-0181-z · 2007 · External reference
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
10.1007/s00520-017-3629-4 · 2017 · External reference
The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies
10.3322/caac.21704 · 2022 · External reference
Oral mucositis: the hidden side of cancer therapy
10.1186/s13046-020-01715-7 · 2020 · External reference
Anti-epidermal growth factor receptor targeted therapy-associated ulcerations
10.1016/j.oraloncology.2023.106660 · 2024 · External reference
Pathogenesis of oral toxicities associated with targeted therapy and immunotherapy
10.3390/ijms24098188 · 2023 · External reference
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
10.1093/annonc/mdw611 · 2017 · External reference
Gender differences in EGFR-TKI-related adverse events: A pharmacovigilance study based on the FAERS database
10.1177/10732748261452789 · 2026 · External reference
Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: A disproportionality analysis of FDA adverse event reporting system
10.1038/s41598-020-61571-5 · 2020 · External reference
Stomatitis associated with osimertinib in advanced lung cancer treatment: Characterization and implications for management
10.1016/j.lungcan.2020.12.004 · 2021 · External reference
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
10.1186/s12885-024-11891-w · 2024 · External reference
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib
10.1038/s41598-022-23834-1 · 2022 · External reference
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study
10.1186/s12885-018-4862-z · 2018 · External reference
Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis
10.1016/j.critrevonc.2021.103393 · 2021 · External reference
EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
10.1186/s12885-024-13168-8 · 2024 · External reference
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
10.7326/m14-2385 · 2015 · External reference
Automating network meta-analysis
10.1002/jrsm.1054 · 2012 · External reference
Conceptual and technical challenges in network meta-analysis
10.7326/0003-4819-159-2-201307160-00008 · 2013 · External reference
Markov chain Monte Carlo methods in biostatistics
10.1177/096228029600500402 · 1996 · External reference
Random-effects meta-analysis of few studies involving rare events
10.1002/jrsm.1370 · 2020 · External reference
On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis
10.1002/jrsm.1475 · 2021 · External reference
Risk of depression in the adolescent and adult offspring of mothers with perinatal depression: A systematic review and meta-analysis
10.1001/jamanetworkopen.2020.8783 · 2020 · External reference
Propofol and survival: an updated meta-analysis of randomized clinical trials
10.1186/s13054-023-04431-8 · 2023 · External reference
Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
10.1136/bmj.k4029 · 2018 · External reference
Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis
10.1038/s41598-022-22431-6 · 2022 · External reference
CINeMA: An approach for assessing confidence in the results of a network meta-analysis
10.1371/journal.pmed.1003082 · 2020 · External reference
EGF-ERBB signalling: towards the systems level
10.1038/nrm1962 · 2006 · External reference
Untangling the ErbB signalling network
10.1038/35052073 · 2001 · External reference
Transcriptional signature primes human oral mucosa for rapid wound healing
10.1126/scitranslmed.aap8798 · 2018 · External reference
Physiologic levels of epidermal growth factor in saliva stimulate cell migration of an oral epithelial cell line, HO-1-N-1
10.1034/j.1600-0722.2002.11179.x · 2002 · External reference
Upregulation of epidermal growth factor receptor 4 in oral leukoplakia
10.1038/ijos.2013.10 · 2013 · External reference
Oral mucosal injury caused by targeted cancer therapies
10.1093/jncimonographs/lgz012 · 2019 · External reference
The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF
10.1053/j.gastro.2008.09.023 · 2009 · External reference
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
10.1093/emboj/16.7.1647 · 1997 · External reference
EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-XL
10.1038/sj.onc.1201657 · 1998 · External reference
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation
10.1016/s0002-9440(10)63654-1 · 2003 · External reference
The pathobiology of mucositis
10.1038/nrc1318 · 2004 · External reference
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
10.1200/jco.2011.40.9433 · 2012 · External reference
The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
10.18632/oncotarget.5286 · 2015 · External reference
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
10.1056/nejmoa1411817 · 2015 · External reference
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
10.1158/2159-8290.cd-14-0326 · 2014 · External reference
Wound repair and regeneration: mechanisms, signaling, and translation
10.1126/scitranslmed.3009337 · 2014 · External reference
Role of salivary vascular endothelial growth factor (VEGF) in palatal mucosal wound healing
10.1111/wrr.12065 · 2013 · External reference
Pharmacovigilance analysis of drug-induced stomatitis: Insights from twenty-one years of real-world data
10.1016/j.identj.2026.109662 · 2026 · External reference
Adverse event profiles of EGFR-TKI: Network meta-analysis and disproportionality analysis of the FAERS database
10.3389/fphar.2025.1519849 · 2025 · External reference
A real-world pharmacovigilance study of dacomitinib based on FDA adverse event reporting system (FAERS) database
10.1007/s00210-026-05389-4 · 2026 · External reference
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
10.1016/j.critrevonc.2021.103305 · 2021 · External reference
Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: A systematic review and network meta-analysis of randomized clinical trials in EGFR-mutant non-small cell lung cancer
10.21037/jtd-24-682 · 2024 · External reference
Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK
10.1007/s40265-015-0434-6 · 2015 · External reference
MASCC/ISOO clinical practice statement: Management of oral complications of targeted therapy
10.1007/s00520-024-08689-8 · 2024 · External reference
Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities
10.1111/ajco.12687 · 2018 · External reference
Prediction of mucositis risk secondary to cancer therapy: A systematic review of current evidence and call to action
10.1007/s00520-020-05579-7 · 2020 · External reference
Chemotherapy-induced and/or radiation therapy-induced oral mucositis--complicating the treatment of cancer
10.1593/neo.04169 · 2004 · External reference
Management strategies for adverse events associated with EGFR TKIs in non-small cell lung cancer
10.6004/jadpro.2016.7.7.4 · 2016 · External reference
Risk of depression in the adolescent and adult offspring of mothers with perinatal depression: A systematic review and meta-analysis
10.1001/jamanetworkopen.2020.8783 · ExternalCitation · doi-reference
Automating network meta-analysis
10.1002/jrsm.1054 · ExternalCitation · doi-reference
Random-effects meta-analysis of few studies involving rare events
10.1002/jrsm.1370 · ExternalCitation · doi-reference
On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis
10.1002/jrsm.1475 · ExternalCitation · doi-reference
A real-world pharmacovigilance study of dacomitinib based on FDA adverse event reporting system (FAERS) database
10.1007/s00210-026-05389-4 · ExternalCitation · doi-reference
Mucosal injury from targeted anti-cancer therapy
10.1007/s00520-006-0181-z · ExternalCitation · doi-reference
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
10.1007/s00520-017-3629-4 · ExternalCitation · doi-reference
Prediction of mucositis risk secondary to cancer therapy: A systematic review of current evidence and call to action
10.1007/s00520-020-05579-7 · ExternalCitation · doi-reference
MASCC/ISOO clinical practice statement: Management of oral complications of targeted therapy
10.1007/s00520-024-08689-8 · ExternalCitation · doi-reference
Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology
10.1007/s40264-018-0772-x · ExternalCitation · doi-reference
Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK
10.1007/s40265-015-0434-6 · ExternalCitation · doi-reference
Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: A meta-analysis
10.1007/s40291-021-00563-1 · ExternalCitation · doi-reference
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
10.1016/j.critrevonc.2021.103305 · ExternalCitation · doi-reference
Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis
10.1016/j.critrevonc.2021.103393 · ExternalCitation · doi-reference
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
10.1016/j.ctrv.2024.102824 · ExternalCitation · doi-reference
Pharmacovigilance analysis of drug-induced stomatitis: Insights from twenty-one years of real-world data
10.1016/j.identj.2026.109662 · ExternalCitation · doi-reference
Stomatitis associated with osimertinib in advanced lung cancer treatment: Characterization and implications for management
10.1016/j.lungcan.2020.12.004 · ExternalCitation · doi-reference
Anti-epidermal growth factor receptor targeted therapy-associated ulcerations
10.1016/j.oraloncology.2023.106660 · ExternalCitation · doi-reference
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation
10.1016/s0002-9440(10)63654-1 · ExternalCitation · doi-reference
Physiologic levels of epidermal growth factor in saliva stimulate cell migration of an oral epithelial cell line, HO-1-N-1
10.1034/j.1600-0722.2002.11179.x · ExternalCitation · doi-reference
Untangling the ErbB signalling network
10.1038/35052073 · ExternalCitation · doi-reference
Upregulation of epidermal growth factor receptor 4 in oral leukoplakia
10.1038/ijos.2013.10 · ExternalCitation · doi-reference
The pathobiology of mucositis
10.1038/nrc1318 · ExternalCitation · doi-reference
EGF-ERBB signalling: towards the systems level
10.1038/nrm1962 · ExternalCitation · doi-reference
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches
10.1038/s41571-025-01085-z · ExternalCitation · doi-reference
Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: A disproportionality analysis of FDA adverse event reporting system
10.1038/s41598-020-61571-5 · ExternalCitation · doi-reference
Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis
10.1038/s41598-022-22431-6 · ExternalCitation · doi-reference
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib
10.1038/s41598-022-23834-1 · ExternalCitation · doi-reference
EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-XL
10.1038/sj.onc.1201657 · ExternalCitation · doi-reference
The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF
10.1053/j.gastro.2008.09.023 · ExternalCitation · doi-reference
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
10.1056/nejmoa1411817 · ExternalCitation · doi-reference
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
10.1093/annonc/mdw611 · ExternalCitation · doi-reference
Overview of current systemic management of EGFR-mutant NSCLC
10.1093/annonc/mdx702 · ExternalCitation · doi-reference
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
10.1093/annonc/mdx704 · ExternalCitation · doi-reference
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
10.1093/emboj/16.7.1647 · ExternalCitation · doi-reference
Oral mucosal injury caused by targeted cancer therapies
10.1093/jncimonographs/lgz012 · ExternalCitation · doi-reference
Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities
10.1111/ajco.12687 · ExternalCitation · doi-reference
Role of salivary vascular endothelial growth factor (VEGF) in palatal mucosal wound healing
10.1111/wrr.12065 · ExternalCitation · doi-reference
Wound repair and regeneration: mechanisms, signaling, and translation
10.1126/scitranslmed.3009337 · ExternalCitation · doi-reference
Transcriptional signature primes human oral mucosa for rapid wound healing
10.1126/scitranslmed.aap8798 · ExternalCitation · doi-reference
Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
10.1136/bmj.k4029 · ExternalCitation · doi-reference
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
10.1158/2159-8290.cd-14-0326 · ExternalCitation · doi-reference
Markov chain Monte Carlo methods in biostatistics
10.1177/096228029600500402 · ExternalCitation · doi-reference
Gender differences in EGFR-TKI-related adverse events: A pharmacovigilance study based on the FAERS database
10.1177/10732748261452789 · ExternalCitation · doi-reference
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study
10.1186/s12885-018-4862-z · ExternalCitation · doi-reference
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
10.1186/s12885-024-11891-w · ExternalCitation · doi-reference
EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
10.1186/s12885-024-13168-8 · ExternalCitation · doi-reference
Oral mucositis: the hidden side of cancer therapy
10.1186/s13046-020-01715-7 · ExternalCitation · doi-reference
Propofol and survival: an updated meta-analysis of randomized clinical trials
10.1186/s13054-023-04431-8 · ExternalCitation · doi-reference
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
10.1200/jco.2011.40.9433 · ExternalCitation · doi-reference
CINeMA: An approach for assessing confidence in the results of a network meta-analysis
10.1371/journal.pmed.1003082 · ExternalCitation · doi-reference
Chemotherapy-induced and/or radiation therapy-induced oral mucositis--complicating the treatment of cancer
10.1593/neo.04169 · ExternalCitation · doi-reference
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
10.18632/oncotarget.12587 · ExternalCitation · doi-reference
The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
10.18632/oncotarget.5286 · ExternalCitation · doi-reference
Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: A systematic review and network meta-analysis of randomized clinical trials in EGFR-mutant non-small cell lung cancer
10.21037/jtd-24-682 · ExternalCitation · doi-reference
The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies
10.3322/caac.21704 · ExternalCitation · doi-reference
Cancer statistics, 2025
10.3322/caac.21871 · ExternalCitation · doi-reference
Adverse event profiles of EGFR-TKI: Network meta-analysis and disproportionality analysis of the FAERS database
10.3389/fphar.2025.1519849 · ExternalCitation · doi-reference
Pathogenesis of oral toxicities associated with targeted therapy and immunotherapy
10.3390/ijms24098188 · ExternalCitation · doi-reference
Management strategies for adverse events associated with EGFR TKIs in non-small cell lung cancer
10.6004/jadpro.2016.7.7.4 · ExternalCitation · doi-reference
Conceptual and technical challenges in network meta-analysis
10.7326/0003-4819-159-2-201307160-00008 · ExternalCitation · doi-reference
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
10.7326/m14-2385 · ExternalCitation · doi-reference
